Anti-Müllerian hormone and polycystic ovary syndrome: assessment of the clinical pregnancy rates in in vitro fertilization patients

References

• Franks S, Hardy K. Aberrant follicle development and anovulation in polycystic ovary syndrome. Ann Endocrinol (Paris) 2010;71:228–30
   PubMed Web of Science ®Google Scholar
• Pellatt L, Hanna L, Brincat M, et al. Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab 2007;92:240–5
   PubMed Web of Science ®Google Scholar
• Desforges-Bullet V, Gallo C, Lefebvre C, et al. Increased anti-Müllerian hormone and decreased FSH levels in follicular fluid obtained in women with polycystic ovaries at the time of follicle puncture for in vitro fertilization. Fertil Steril 2010;94:198–204
   PubMed Web of Science ®Google Scholar
• Piouka A, Farmakiotis D, Katsikis I, et al. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab 2009;296:E238–43
   PubMed Web of Science ®Google Scholar
• Georgopoulos NA, Saltamavros AD, Decavalas G, et al. Serum AMH, FSH, and LH levels in PCOS. Fertil Steril 2010;93:e13
   PubMed Web of Science ®Google Scholar
• Singer T, Barad DH, Weghofer A, Gleicher N. Correlation of anti-Müllerian hormone and baseline follicle-stimulating hormone levels. Fertil Steril 2009;91:2616–19
   PubMed Web of Science ®Google Scholar
• Sahmay S, Guralp O, Senturk LM, et al. Serum anti-Mullerian hormone concentrations in reproductive age women with and without polycystic ovary syndrome: the influence of body mass index. Reprod Med Biol 2011;10:113–20
   PubMedGoogle Scholar
• Ocal P, Sahmay S, Cetin M, et al. Serum anti-Müllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles. J Assist Reprod Genet 2011;28:1197–203
   PubMed Web of Science ®Google Scholar
• La Marca A, Pati M, Orvieto R, et al. Serum anti-Müllerian hormone levels in women with secondary amenorrhea. Fertil Steril 2006; 85:1547–9
   PubMed Web of Science ®Google Scholar
• Panidis D, Katsikis I, Karkanaki A, et al. Serum anti-Müllerian hormone (AMH) levels are differentially modulated by both serum gonadotropins and not only by serum follicle stimulating hormone (FSH) levels. Med Hypotheses 2011;77:649–53
   PubMed Web of Science ®Google Scholar
• Irez T, Ocal P, Guralp O, et al. Different serum anti-Müllerian hormone concentrations are associated with oocyte quality, embryo development parameters and IVF-ICSI outcomes. Arch Gynecol Obstet 2011; 284:1295–301
   PubMed Web of Science ®Google Scholar
• Ebner T, Sommergruber M, Moser M, et al. Basal level of anti-Müllerian hormone is associated with oocyte quality in stimulated cycles Basal level of anti-Müllerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod 2006;21:2022–6
   PubMed Web of Science ®Google Scholar
• The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reprod 2004;19:41–7
   PubMed Web of Science ®Google Scholar
• Hazout A, Bouchard P, Seifer DB, et al. Serum anti-Müllerian hormone/Müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril 2004;82:1323–9
   PubMed Web of Science ®Google Scholar
• Nelson SM, Yates RW, Fleming R. Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles – implications for individualization of therapy. Hum Reprod 2007;22:2414–21
   PubMed Web of Science ®Google Scholar
• Majumder K, Gelbaya TA, Laing I, Nardo LG. The use of anti-Müllerian hormone and antral follicle count to predict the potential of oocytes and embryos. Eur J Obstet Gynecol Reprod Biol 2010;150:166–70
   PubMed Web of Science ®Google Scholar
• Wu CH, Chen YC, Wu HH, et al. Serum anti-Müllerian hormone predicts ovarian response and cycle outcome in IVF patients. J Assist Reprod Genet 2009; 26:383–9
   PubMed Web of Science ®Google Scholar
• Sahmay S, Demirayak G, Guralp O, et al. Serum anti-Müllerian hormone, follicle stimulating hormone and antral follicle count measurement cannot predict pregnancy rates in IVF/ICSI cycles. J Assist Reprod Genet 2012;29:589–95
   PubMed Web of Science ®Google Scholar
• Tremellen K, Kolo M. Serum anti-Mullerian hormone is a useful measure of quantitative ovarian reserve but does not predict the chances of live-birth pregnancy. Aust N Z J Obstet Gynaecol 2010;50:568–72
   PubMed Web of Science ®Google Scholar
• Deffieux X, Antoinne JM. Inhibins, activins and anti-Müllerian hormone: structure, signalling pathways, roles and predictive value in reproductive medicine. Gynecol Obstet Fertil 2003;31:900–11
   PubMedGoogle Scholar
• Penarrubia J, Fabregues F, Manau D, et al. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist-gonadotropin treatment. Hum Reprod 2005;20:915–22
   PubMed Web of Science ®Google Scholar
• Xi W, Gong F, Lu G. Correlation of serum anti-Müllerian hormone concentrations on day 3 of the in vitro fertilization stimulation cycle with assisted reproduction outcome in polycystic ovary syndrome patients. J Assist Reprod Genet 2012;29:397–402
   PubMed Web of Science ®Google Scholar
• Aleyasin A, Aghahoseini M, Mokhtar S, Fallahi P. Anti-Mullerian hormone as a predictive factor in assisted reproductive technique of polycystic ovary syndrome patients. Acta Med Iran 2011;49:715–20
   PubMedGoogle Scholar
• Kaya C, Pabuccu R, Satıroglu H. Serum anti-Müllerian hormone concentrations on day 3 of the in vitro fertilization stimulation cycle are predictive of the fertilization, implantation, and pregnancy in polycystic ovary syndrome patients undergoing assisted reproduction. Fertil Steril 2010;94:2202–7
   PubMed Web of Science ®Google Scholar
• Li L, Chen X, Mo Y, et al. Elevated serum anti-Mullerian hormone in adolescent and young adult Chinese patients with polycystic ovary syndrome. Wien Klin Wochenschr 2010;122:519–24
   PubMed Web of Science ®Google Scholar
• Hart R, Doherty DA, Norman RJ, et al. Serum antimullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS). Fertil Steril 2010;94:1118–21
   PubMed Web of Science ®Google Scholar
• Pigny P, Merlen E, Robert Y, et al. Elevated serum level of anti-Mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003;88:5957–62
   PubMed Web of Science ®Google Scholar
• Broer SL, Mol BW, Hendriks D, Broekmans FJ. The role of anti-Mullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril 2009;91:705–14
   PubMed Web of Science ®Google Scholar
• Heijnen EM, Eijkemans MJ, Hughes EG, et al. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum Reprod Update 2006;12:13–21
   PubMed Web of Science ®Google Scholar